Treatment of recurrent high-grade gliomas

Current Opinion in Neurology

Volumn 22, Issue 6, 2009, Pages 657-664

  Wen, Patrick Y ^a   Brandes, Alba A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MAGGIORE HOSPITAL   (Italy)

Author keywords

Angiogenesis; Glioblastoma; Surgery; Targeted molecular therapy

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CEDIRANIB; CT 322; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FOTEMUSTINE; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NIMUSTINE; PAZOPANIB; PF 299804; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; XL 184;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BLEEDING; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN SURGERY; CANCER RADIOTHERAPY; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG PENETRATION; DRUG TARGETING; GLIOBLASTOMA; HUMAN; HYPERTENSION; INFECTION; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; GENE THERAPY; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY;

EID: 74049083639     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32833229e3     Document Type: Review

References (101)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
3. Hegi ME, Diserens AC, Gorlia T, etal. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
4. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17:2572-2578.
5. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-oncol 2008; 10:162-170.
6. Ballman K, Buckner J, Brown P, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-oncol 2007; 9:29-38.
7. Franceschi E, Tosoni A, Bartolini S, et al. Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Rev Anticancer Ther 2009; 9:613-619.
8. Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9:453-461.
9. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirra-diation with temozolomide. Cancer 2008; 113:405-410.
10. Gerstner ER, McNamara MB, Norden AD, et al. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neuro-oncol 2009; 94:97-101.
11. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26:2192-2197.
12. Keles GE, Lamborn KR, Chang SM, et al. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 2004; 100:41-46.
13. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95:190-198.
14. Barker FG 2nd, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998; 42:709-720.
15. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.[comment]. J Neurosurg 2001; 95:190-198.
16. Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 2006; 24:1273-1280.
17. Combs SE, Thilmann C, Edler L, et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 2005; 23:8863-8869. (Pubitemid 46211533)
18. Tsao MN, Mehta MP, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 2005; 63:47-55.
19. Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007; 25:4033-4042.
20. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009; 75:156-163.
21. van den Bent MJ. Anaplastic oligodendroglioma and oligoastrocytoma. Neurol Clin 2007; 25:1089-1109.
22. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoas-trocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999; 17:2762-2771.
23. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83:588-593.
24. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 2009; 11:80-91.
25. Fine HA, Puduvalli VK, Chamberlain MC, et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): a phase III study. J Clin Oncol 2008; 26:2005.
26. Brandes AA, Tosoni A, Franceschi E, et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 2009; 64:769-775.
27. Happold C, Roth P, Wick W, et al. ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol 2009; 92:45-48.
28. Brandes AA, Tosoni A, Basso U, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 2004; 22:4779-4786.
29. Wick A, Pascher C, Wick W, et al. Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 2009; 256:734-741.
30. Perry J, Mason W, Belanger K, et al. The temozolomide RESCUE study: A phase II trial of continuous 28/28 dose-intense temozolomide after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma. Neuro-Oncology 2008; 10:1063.
31. Brandes AA, Franceschi E, Tosoni A, et al. Change in MGMT methylation status between first and second surgery. J Clin Oncol 2009; 27:15s.
32. Quinn JA, Jiang SX, Reardon DA, et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 2009; 27:1262-1267.
33. Quinn JA, Jiang SX, Reardon DA, et al. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol 2009. [Epub ahead of print]
34. Quinn JA, Jiang SX, Reardon DA, et al. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer 2009; 115:2964-2970.
35. Quinn JA, Jiang SX, Carter J, et al. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res 2009; 15:1064-1068.
36. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009; 15:4622-4629.
37. Cahill DP, Codd PJ, Batchelor TT, et al. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. Clin Neurosurg 2008; 55:165-171.
38. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent malignant gliomas: The Polymer-brain Tumor Treatment Group. Lancet 1999;345:1008-1012.
39. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-1068.
40. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1812.
41. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-773.
42. Bredel M, Scholtens DM, Harsh GR, et al. A network model of a cooperative genetic landscape in brain tumors. JAMA 2009; 302:261-275.
43. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21:2683-2710.
44. Chi A, Wen P. Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets 2007; 11:473-496.
45. Sathornsumetee S, Reardon DA, Desjardins A, et al. Molecularly targeted therapy for malignant glioma. Cancer 2007; 110:13-24.
46. Idbaih A, Ducray F, Sierra Del Rio M, et al. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. Oncologist 2008; 13:978-992.
47. Rich J, Reardon DA, Peery T, et al. Phase II trial of ZD-1839 for patients with first relapse glioblastoma. J Clin Oncol 2004; 22:133-142.
48. Franceschi E, Cavallo G, Lonardi S, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2007; 96:1047-1051.
49. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009; 27:1268-1274.
50. Wen P, Yung W, Lamborn K, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006; 12:4899-4907. (Pubitemid 44338577)
51. Raymond E, BrandesAA, DittrichC, etal. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008; 26:4659-4665.
52. Cloughesy TF, Wen PY, Robins HI, etal. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006; 24:3651-3656.
53. Lustig R, Mikkelsen T, Lesser G, et al. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol 2008; 10:1004-1009.
54. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5:e8.
55. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729. (Pubitemid 350086473)
56. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008; 112:2267-2273.
57. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009; 72: 1217-1222.
58. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-745.
59. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70:779-787.
60. Chang S, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005; 23:357-361.
61. Galanis E, Jaeckle KA, Maurer MJ, etal. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009; 27:2052-2058.
62. Friedman H, Prados M, Wen P, et al. A Phase II, Randomized, Non-Comparative Clinical Trial of Bevacizumab Alone or in Combination with Irinotecan in Recurrent Glioblastoma. J Clin Oncol 2009. [Epub ahead of print].
63. Sathornsumetee S, Reardon DA. Targeting multiple kinases in glioblastoma multiforme. Expert Opin Investig Drugs 2009; 18:277-292.
64. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318:287-290.
65. Wen PY. New developments in targeted molecular therapies for glioblastoma. Expert Rev Anticancer Ther 2009; 9:7-10.
66. Mellinghoff I, Wang M, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-2024.
67. Haas-Kogan D, Prados M, Lamborn K, etal. Biomarkersto predict response to epidermal growth factor receptor inhibitors. Cell Cycle 2005; 4:1369-1372. (Pubitemid 41437124)
68. Brown PD, Krishnan S, Sarkaria JN, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 2008; 26:5603-5609.
69. Chang SM, J. Kuhn J, Lamborn K, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). J Clin Oncol 2009; 27:89S.
70. Wen PY, Cloughesy T, Kuhn J, et al. Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J Clin Oncol 2009; 27:89s.
71. Prados MD, Gilbert M, Kuhn J, etal. Phase I/II study of sorafenib and erlotinib for patients with recurrent glioblastoma (NABTC 05-02). J Clin Oncol 2009; 27:89s.
72. Stiles CD, Rowitch DH. Glioma stem cells: a midterm exam. Neuron 2008; 58:832-846.
73. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radio-resistance by preferential activation of the DNA damage response. Nature 2006; 444:756-760.
74. Das S, Srikanth M, Kessler JA. Cancer stem cells and glioma. Nat Clin Pract Neurol 2008; 4:427-435.
75. Chang SM, Lamborn KR, Kuhn JG, etal. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro-oncol 2008; 10:631-642.
76. Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 2009; 6:513-526.
77. Gerstner ER, Sorensen AG, Jain RK, Batchelor TT. Antivascular endothelial growth factor therapy for malignant glioma. Curr Neurol Neurosci Rep 2009; 9:254-262.
78. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. In World Federation of Neuro-Oncology Second Quadrennial Meeting; Edinburgh, Scotland: 2005:Abstract 342.
79. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13:1253-1259.
80. Norden AD, Drappatz J, Ciampa AS, et al. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro-oncol 2009; 11:92-95.
81. Norden AD, Drappatz J, MuzikanskyA, etal. An exploratory survival analysis of antiangiogenic therapy for recurrent malignant glioma. J Neurooncol 2009; 92:149-155.
82. Gerstner ER, DudaDG, diTomaso E, et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009; 6:229-236.
83. BatchelorT, Sorensen A, diTomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95.
84. Kamoun WS, Ley CD, FarrarCT, etal. Edema control bycediranib, avascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009; 27:2542-2552.
85. Macdonald D, Cascino T, Schold SJ, Cairncross J. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-1280.
86. van den Bent MJ, Vogelbaum MA, Wen PY, et al. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 2009; 27:2905-2908.
87. Chang SM, Clarke J, Wen P. Novel imaging response assessment for drug therapies in recurrent malignant glioma. Asco educational book 2009; 2009: 107-111.
88. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008; 8:592-603.
89. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endo thelial growth factor-targeted therapy. Clin Cancer Res 2008; 14:6371-6375.
90. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-231.
91. Lucio-Eterovic AK, Piao Y, deGroot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009; 15:4589-4599.
92. Drappatz J, Norden AD, Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother 2009; 9:519-534.
93. Du J, Bernasconi P, Clauser KR, etal. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 2009; 27:77-83.
94. de Groot J, Milano V. Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. J Neurooncol 2009. [Epub ahead of print]
95. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26:5610-5617.
96. Stupp R, Goldbrunner R, Neyns B, et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol (Meeting Abstracts) 2007; 25:2000.
97. Parker JN, Bauer DF, Cody JJ, Markert JM. Oncolytic viral therapy of malignant glioma. Neurotherapeutics 2009; 6:558-559
98. Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated preand posttumor resection for recurrent GBM. Mol Ther 2009; 17:199-207.
99. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008; 68:5955-5964.
100. Sampson JH, Akabani G, Archer GE, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-oncol 2008; 10:320-329.
101. Abrey LE, Louis DN, Paleologos N. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro-oncol 2007; 9:314-318.